Try our beta test site
11 studies found for:    hepatitis delta | Open Studies | hepatitis D
Show Display Options
Rank Status Study
1 Recruiting The Hepatitis Delta International Network
Condition: Hepatitis D
Intervention:
2 Recruiting A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
Condition: Hepatitis D, Chronic
Intervention: Drug: Lambda
3 Recruiting Mother-to-child Hepatitis D Transmission
Conditions: Hepatitis D;   Transmission
Intervention:
4 Not yet recruiting A Study of Lonafarnib With or Without Ritonavir in Patients With HDV
Condition: Chronic Delta Hepatitis
Interventions: Drug: Lonafarnib;   Drug: Ritonavir
5 Recruiting Lonafarnib With Ritonavir in HDV (LOWR-2)
Condition: Chronic Hepatitis D Infection
Interventions: Drug: lonafarnib;   Drug: Ritonavir;   Drug: PEG IFN-a
6 Recruiting Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Conditions: Human Immunodeficiency Virus;   HBV;   Fibrosis, Liver;   Cirrhosis, Liver;   Hepatocellular Carcinoma;   Hepatitis Delta Virus;   Alcoholic Hepatitis
Intervention: Drug: Anti-HIV Agents
7 Recruiting Evaluation of Patients With Liver Disease
Conditions: Biliary Liver Cirrhosis;   Hemochromatosis;   Hepatitis;   Hepatolenticular Degeneration;   Liver Disease
Intervention:
8 Not yet recruiting Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma
Conditions: Hepatitis B;   Carcinoma, Hepatocellular
Intervention: Drug: Vitamin D3
9 Recruiting The Relationship Between Vitamin D and Hepatitis B Virus Replication
Condition: Vitamin D and Hepatitis B Virus
Intervention: Dietary Supplement: Vitamin D
10 Recruiting Quality of Life Measurement in Treatment Naïve Patients With HCV Genotype 1 Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)
Condition: Chronic Hepatitis C Virus (HCV)
Intervention:
11 Recruiting Treatment of Recently Acquired Genotype 1 Hepatitis C With the 3D Regimen
Condition: Hepatitis C, Acute
Interventions: Drug: Paritaprevir/ritonavir/ombitasvir;   Drug: Dasabuvir;   Drug: Ribavirin

Study has passed its completion date and status has not been verified in more than two years.